Intismeran Hits Phase 3 Melanoma Endpoints

This is a major validation of personalized oncology, though it is not an AI product itself; computational biology enables the individualized treatment design.

• –First positive Phase 3 result for an individualized neoantigen therapy and mRNA-based cancer treatment
• –INTerpath-001 compared intismeran plus Keytruda against Keytruda alone in completely resected stage IIB-IV melanoma
• –The result could strengthen Moderna’s post-COVID oncology strategy and expand its partnership with Merck
• –Upcoming detailed data will determine the magnitude of benefit, safety profile, manufacturing complexity, and regulatory path
• –Success in melanoma will not automatically translate to other cancers, where tumor biology and mutation profiles differ